Unknown

Dataset Information

0

Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia.

ABSTRACT:

SUBMITTER: Akiyama H 

PROVIDER: S-EPMC12022017 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors.
| S-EPMC9529991 | biostudies-literature
Unknown Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
| S-EPMC5562278 | biostudies-literature
Unknown Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
| S-EPMC5623739 | biostudies-literature
Unknown Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.
| S-EPMC4287641 | biostudies-literature
Transcriptomics Oncofetal gene reactivation drives EZH2-mutant myeloid leukemia pathogenesis
2023-04-30 | GSE173497 | GEO
Unknown Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells.
| S-EPMC10076884 | biostudies-literature
Unknown Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.
| S-EPMC12860451 | biostudies-literature
Unknown Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia.
| S-EPMC11808118 | biostudies-literature
Unknown Lysosomes in Stem Cell Quiescence: A Potential Therapeutic Target in Acute Myeloid Leukemia.
| S-EPMC8996909 | biostudies-literature
Proteomics RHOF Activation of AKT/β-Catenin Signaling Pathway Drives Acute Myeloid Leukemia Progression and Chemotherapy Resistance
2024-05-09 | PXD052126 |